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Systemic lupus erythematosus (SLE) is the prototypic systemic autoimmune disease. It is
thought that many common variant gene loci of weak effect act additively to predispose to
common autoimmune diseases, while the contribution of rare variants remains unclear. Here
we describe that rare coding variants in lupus-risk genes are present in most SLE patients and
healthy controls. We demonstrate the functional consequences of rare and low frequency
missense variants in the interacting proteins BLK and BANK1, which are present alone, or in
combination, in a substantial proportion of lupus patients. The rare variants found in patients,
but not those found exclusively in controls, impair suppression of IRF5 and type-I IFN in
human B cell lines and increase pathogenic lymphocytes in lupus-prone mice. Thus, rare gene
variants are common in SLE and likely contribute to genetic risk.
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Systemic lupus erythematosus (SLE) is a highly hetero-geneous autoimmune disease in terms of both clinicalphenotypes and underlying pathophysiology. Examination
of disordered immune function in patients and animal models of
lupus have implicated a diverse range of mechanisms contribut-
ing to disease. B-cell hyperreactivity and breaks in B-cell tolerance
caused by B-cell intrinsic and extrinsic factors often involving
TLR7 signaling are central to disease pathogenesis1–4. The most
consistent final common feature in human SLE patients is over-
production of type I interferon (T1 IFN)5,6. Monogenic inter-
feronopathies exemplify this contribution, providing crucial
insights into how mutations affecting different genes in different
patients lead to excess T1 IFN and develop similar clinical
manifestations that overlap with severe SLE7. Concordance for
lupus between monozygotic twins is approximately 50%, indi-
cating that even in sporadic disease there is a substantial genetic
contribution to aetiology8. While familial aggregation is well
recognised, inheritance follows complex non-Mendelian pat-
terns9. Variants identified by genome-wide association studies
(GWAS) in genes such as STAT4, IRAK110, and LYN are plau-
sible by their consistency with prior observations, rather than
empirical evidence of pathogenicity11. The prevalent hypothesis
to explain the observation of common allelic frequency and
modest effect size is that it is the cumulative or epistatic effect of
multiple GWAS single-nucleotide polymorphisms (SNPs) in
addition to environmental factors that result in predisposition to
SLE12–16. Lupus is often a devastating disease in women of
childbearing age, which might argue against the aggregate con-
tribution of common genetic variants. Another hypothesis is that
in some cases SLE arises from rare genetic variants with strong
effects. Rare (MAF < 0.005) and low frequency (MAF < 0.02)
variants are known to contribute to complex hereditary traits15
and can explain sporadic disease in the case of de novo muta-
tions15–17. These disease-predisposing rare variants can be in
linkage disequilibrium with GWAS-identified SNPs due to co-
inheritance in shared haploblocks18 and may contribute to the
missing heritability in common autoimmune diseases.
In this study we examine the role of rare and low-frequency
variants in systemic autoimmunity. We identified several rare
variants in BLK and BANK1 in healthy controls and patients with
SLE. BLK variants found in SLE patients impaired the kinase
activity of BLK. We demonstrate that BLK is capable of repressing
IRF5-mediated interferon-β expression (IFNβ), and that loss of
BLK kinase activity caused by the rare variants enhanced
interferon-β production. In contrast rare variants in BLK found
exclusively in healthy controls did not substantially impair
interferon-β repression. As expected, SLE patients with rare BLK
variants also had increased expression of interferon signature
genes compared to healthy controls. Mice bearing a Blk variant
orthologous to one found in an SLE patient have exacerbated
accumulation of pathogenic lymphoid cells when crossed to
lupus-prone mice. We observe that low-frequency mutations in
BLK’s epistatic partner BANK1, impair BANK1′s ability to
sequester IRF5 from the nucleus. Together these data identify a
novel function for BANK1 and BLK in repression of type I IFN
and demonstrate how rare variants in SLE risk genes increase
type 1 interferon activity which is central to development of
autoimmunity.
Results
SLE patients have rare coding variants in SLE-risk genes. To
investigate the prevalence of rare variants in lupus-risk genes we
selected an initial 69 SLE probands (SLE1), a replication cohort of
64 SLE probands (SLE2) and 97 healthy elderly individuals
without a history of chronic disease. The SLE cohort comprised
pediatric-onset (14%), adolescent-onset (26%), and adult-onset
(55%) SLE and four patients whose age of disease onset was
unknown. The genetically determined ethnicity of the two
cohorts was predominantly European with 79.7% of SLE patients
and 100% of healthy controls of European ethnicity (Supple-
mentary Data 1). Healthy controls underwent whole-genome
sequencing (WGS) as did 12.7% of SLE patients, and the
remainder whole-exome sequencing (WES). We identified rare
(minor allele frequencies (MAF) below 0.005 specific to the
individual’s ethnicity) missense and splice site (bases up to +/−6
from the exon border) variants.
We generated a list of all identified lupus-associated genes
including all monogenic causes of SLE10,19,20, known causes of
interferonopathies21 which share many features of SLE, and all
GWAS SLE loci for which there are reported human expression
quantitative trait loci, or occur in a coding region, or for which
there is evidence of association with lupus from mouse
studies10,19,22. This resulted in a list of 76 SLE genes
(Supplementary Data 2). Totally, 82% of SLE patients carried
rare nonsynonymous variants in SLE-associated genes as did 72%
of healthy controls. In all, 48% of all patients had 1 or 2 rare
variants, 30% had 3–5, and 3% had >5 rare variants. Variants
found in both SLE patients and healthy controls were
predominantly missense mutations. There was no difference in
the distribution of the type of nonsynonymous variants
(missense, nonsense, and splice site) between patients and healthy
controls (Supplementary Fig. 1). SLE patients harboured on
average two rare variants in lupus-gene loci (Fig. 1a). Comparison
of rare variant and Immunochip SLE-associated common
variants in the 76 genes did not demonstrate a correlation in
the number of rare variants and common risk alleles (Fig. 1b).
These findings demonstrate that rare gene coding variants in SLE-
associated genes are found in most SLE patients.
Variants in BLK and BANK1 segregate with autoimmune dis-
ease. We next asked whether the rare variants observed in
patients with SLE confer functional defects. For this we asked
which lupus-associated genes harboured the rare variants in our
cohort. Of the 76 genes, there were 20 genes with variants in ≥3
SLE patients (2.3%) and a prevalence ≥1.5 times that seen in
controls (Fig. 1c, Table S2). BLK, LYST, TYK2, UHRF1BP1, and
IKBKE were the genes most frequently containing rare variants in
SLE patients. To test the contribution of rare variants to disease,
we next turned to complementary functional studies.
We started by looking at the SNV in BLK given the high
frequency of rare variants in this gene. BLK was also chosen
because multiple common variants tagging BLK (rs2248932,
MAF: 0.49; rs2736340, MAF: 038; and rs13277113, MAF: 0.36)
have been identified as SLE-predisposing by GWAS (OR= 1.39
[95% CI: 1.28–1.51])14,23,24 and a large scale Immunochip
study25. Also, BLK in humans is expressed in B cells and
plasmacytoid dendritic cells26, two cell types considered to be
important for SLE development. The BLK GWAS variants
reported to date are noncoding and suggested to overlap with
regulatory elements leading to reduced BLK gene expression27. In
the initial SLE cohort we identified 6 rare or novel SNV in BLK
(BLKR131W rs73663163, BLKR131Q rs144615291, BLKR238Q
rs141865425, BLKP307R novel, BLKY350H rs758750492, and
BLKR359C rs146505280, and BLKR359C rs146505280) in 14
patients and an additional low-frequency variant BLKA71T
(rs55758736, MAF= 0.012) in 5 patients (Fig. 2a and Table 1).
Thus, 10.1% of our original SLE patients (SLE1, n= 7 of 69)
(Fig. 2a) and 10.9% of our replication cohort (SLE2, n= 7 of 64)
had a rare or novel missense SNV in BLK. Rare or novel missense
SNVs in BLK were found at significantly lower frequencies in a
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common variable immunodeficiency/complex immunodeficiency
(CVID/CID) cohort (n= 3 of 107, 2.8%, p⩽ 0.02) but at
comparable frequency in healthy controls (n= 7 of 97, 7.2%, p
= 0.5). Synonymous SNV of any allelic frequency in BLK were
found at equivalent rates in all three cohorts (Fig. 2b).
All relatives with systemic autoimmunity in the pedigrees of
probands with BLK rare alleles also carried the BLK variants,
however, 25% of individuals carrying the variants did not have
disease. While there are multiple factors shown to contribute to
incomplete gene penetrance (gender, environmental influences,
epigenetic changes, combined effects of risk and protective
common alleles, etc.), we considered the possibility of additional
SLE rare variants acting in epistasis with BLK being present in
subjects with disease. In search for variants in BLK- interacting
proteins, we identified 2 families in which there was co-
segregation in patients with autoimmune disease of a rare BLK
SNV with a rare and a low-frequency mutation in B-Cell Scaffold
Protein With Ankyrin Repeats 1 (BANK1) (BANK1D400G
rs201960198, ExAC MAF < 0.00007 and BANK1W40C
rs35978636, ExAC MAF:0.0103), respectively). BANK1 expres-
sion is also restricted to B cells and plasmacytoid dendritic
cells28,29, is associated with SLE by GWAS12 and a large scale
Immunochip study25, and has been reported to function in
epistasis with BLK30 (Fig. 2c).
Interestingly, we noted that the GWAS-associated SNP
(4:101829919 G/A; BANK1R61H, MAF 0.25, odds ratio (OR)=
1.4 [95% confidence interval (CI): 1.3–1.5], p= 3.74 × 10−10),
tags a common BANK1 haplotype12,14 and is likely in linkage
disequilibrium with the low-frequency BANK1W40C in our SLE
cohort (Supplementary Fig. 2); both SNVs occur within exon 2.
We hypothesised that, like the BANK1R61H GWAS SNP,
BANKW40C may be observed at high frequency in SLE patients.
Indeed, when we searched for this variant in a third cohort
comprised of 150 SLE patients (for which the DNA yield and
quality was insufficient for WES, but adequate for a targeted
polymerase chain reaction (PCR)-amplifluor assay), we identified
the BANK1W40C SNV in 9 SLE probands (6%) and in 3 out of 222
unaffected controls (n= 3 of 222, 1.3%) resulting in an OR of 4.7
(95% CI: 1.1–27.1, p= 0.017) (Fig. 2d). No further low-frequency
or novel BANK1 variants were found in the SLE cohort (Fig. 2e).
Together these data demonstrate that a substantial fraction of SLE
patients have one of multiple rare- or low-frequency SNVs in
BANK1 and/or BLK.
BLK SNVs impair phosphorylation of BANK1 and IRF5. We
next examined the effect of the BLK and BANK1 SNVs on
protein function. We noted that many of the BLK SNVs iden-
tified are in functionally important regions of the protein. The
arginine residue at position 238, mutated in families D and G, is
strictly conserved in all Src-family kinases. In the resolved
protein crystal structures this residue is seen to orient the SH2-
kinase linker with the N-lobe of the kinase domain via an
interaction with P30731, which is mutated in family N (Fig. 3a).
Mutation of the analogous R238 residue in Src has been shown
to inhibit its catalytic activity31. In addition, the arginine resi-
due at position 131, mutated in families A and C, is conserved
in many SH2 domains and assists in the coordination of bound
phosphotyrosines. The tyrosine at 350, mutated in family J,
resides within the kinase domain and we hypothesized would
restrict BLK catalytic activity. BLKA71T is known to reduce
protein stability and thus minimize available protein32.
Therefore, we postulated that the identified SNVs would alter
kinase activity of BLK by impairing availability of protein or
protein function. BLK expressed in heterologous cell lines
translates a higher molecular weight active band due to rela-
tively higher phosphorylation, and a lower molecular weight
inactive band33. As expected, upon transfection of BLKR131W,
BLKR131Q and BLKR238Q into HEK293T cells almost no active
bands were seen, compared with visible active bands in cells
transfected with wild type BLK, BLKY305H and a constitutively
active BLKY501F (Fig. 3b). This suggests that some of the BLK
mutations impair the protein’s ability to acquire an active
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Fig. 1 Large burden of rare nonsynonymous SNV in SLE-related genes in SLE patients. a Pie chart demonstrating burden of variants in two SLE cohorts, SLE1
and SLE2, and 97 elderly healthy controls (HC). The numbering 0–4 indicates the number of rare variants found in a list of 76 GWAS SLE genes. b Number
of SLE GWAS risk alleles in individual SLE patients with indicated number of rare variants (mean and SD, Kruskal–Wallis test). c The most frequently
mutated genes in SLE cohort of 113 probands, shown as the number of total SLE patients and healthy controls (proportion of subjects) with variants in each
individual gene
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conformation. As BLK is known to phosphorylate BANK1 and
SNVs were identified in both genes in the three patients, we
tested whether the identified BLK variants had impaired ability
to phosphorylate BANK1. Indeed, the four rare BLK variants
tested had impaired phosphorylation of BANK1 (Fig. 3c).
Collectively, this demonstrates that rare variants in BLK iden-
tified in a large proportion of SLE patients have significantly
impaired kinase function.
BLK SNV impair repression of IRF5-mediated T1 IFN
expression. We then explored the contribution of rare alleles of
BLK to the pathogenesis of SLE. Since BLK activates PLCG2 and
induces Ca2+ flux upon B-cell receptor (BCR) signaling34, we
tested whether the variant may impair Ca2+ flux in a human B-
cell line (Ramos) in which we introduced the BLKR131W variant
using CRISPR-Cas9 editing. No difference in response to BCR-
mediated Ca2+ flux was observed in BLKR131W/R131W cells
compared with WT cells, excluding this as a potential mechanism
(Supplementary Fig. 3).
BLK is a member of the SrcB kinase subfamily, which includes
LYN. LYN and BLK are both activated by CD79-mediated
phosphorylation upon BCR cross-linking35, and both
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phosphorylate BANK1 after BCR stimulation34. Common alleles
of LYN, like BLK, have been implicated in SLE by GWAS13 and
Lyn deficiency induces a lupus-like phenotype in mice36. Besides
regulating calcium flux36, Lyn deficiency also promotes auto-
immunity through impaired regulation of IRF5-mediated T1 IFN
production and activity11. We thus hypothesized that BLK may
share IRF5 as a substrate with LYN and the hypomorphic BLK
variants may impair IRF5 regulation. Indeed, upon co-expression
of BLK and IRF5 in HEK293T cells, wild-type BLK phosphory-
lated IRF5, whereas the identified rare BLK variants had
diminished or no ability to phosphorylate IRF5 (Fig. 3d).
We next tested whether, as shown for LYN, BLK plays an
active role in the repression of IRF5 and T1 IFN activity.
Expression of the BLK variants with an IFNb dual luciferase
reporter demonstrated that all tested BLK variants (BLKR131W,
BLKR238Q, and BLKY350H) were unable to repress IRF5-mediated
IFNb activity compared to wild-type BLK (Fig. 4a) in a dose-
dependent manner (Supplementary Fig. 4). In addition, using a
CRISPR/Cas9-engineered BLKR131W/R131W human B-cell line we
demonstrated enhanced IFNβ expression in response to stimula-
tion with the TLR7/8 agonist resiquimod (R848) (Fig. 4b).
We also asked whether the rare BLK variants found in SLE
patients were more damaging than those found in healthy
controls. For this we generated plasmids expressing each of the
six rare BLK variants exclusively found in healthy controls
(BLKP39L, BLKH55R, BLKK84N, BLKV101I, BLKR115Q, BLKG248A,
Table 2) and tested side-by-side the repressive ability of all BLK
variants. Five of six rare BLK variants found in patients with SLE
had greater than 50% reduction in IFNβ repression (Fig. 4c)
compared to wild-type BLK, whereas none of the six rare BLK
variants found exclusively in healthy controls had a similar
impairment (p < 0.0001). Consistent with the inability of SLE
patient BLK variants to repress IFNb, examination of peripheral
blood mononuclear cells from family G patients heterozygous for
the BLKR238Q variant (G.I.1, G.II.1, G.II.2, and G.II.3) revealed
upregulation of the T1 IFN signature (Fig. 4c and module M1.2 in
Fig. 4d) as well as apoptosis/survival pathways (module M6.6 in
Fig. 4d, Supplementary Fig. 5). Together these data demonstrate
that rare BLK variants in patients with SLE have impaired
regulation of IFNb expression whereas those found only in
healthy controls do not.
Variants in Blk augment pathogenic T cells in Faslpr mice. We
next tested the effect of the BLK variants on lupus development
in vivo using CRISPR/Cas9-generated mice bearing the ortho-
logue of human BLKR131W, BlkR125W (Fig. 5a). BlkR125W/R125W
mice had normal immune phenotypes comparable to those of
heterozygous and wild type littermates (Supplementary
Fig. 6A). Unlike the human BLKR131W variant, stimulation of
lymphocytes from CRISPR/Cas9-engineered mice expressing
BlkR125W did not reveal an increased T1 IFN response (Sup-
plementary Fig. 6B) consistent with previous studies suggesting
redundancy between Blk and other Src kinases in mice37. The
BlkR125W variant iwas introduced into mice with a genetic
susceptibility to SLE. We chose C57BL/6.Faslpr mice because
Fas.lpr mice in the MRL genetic background develop a syn-
drome that resembles human lupus and Blk haploinsufficiency
exacerbates lupus in MRL.Faslpr mice26. B6.Faslpr mice carrying
a single BlkR125W allele showed significantly expanded CD4/
CD8 double-negative T cells (Fig. 5b), which have been shown
to be important contributors to the hypercellularity in these
Table 1 Comparison of BANK1 and BLK variants found in SLE patients
MAFa Type AA change CADD HC with allele (n) SLE with allele (n)
BLK
GWAS SNPs
rs2248932 0.61 Intron N/A N/A – –
rs13277113 0.25 Intron N/A N/A – –
rs2736340 0.25 Intron N/A N/A – –
NRLF SNPs
rs55758736 0.01 Missense A71T 5.86 1 7
rs73663163 0.0005 Missense R131W 14.93 0 1
rs144615291 0.00004 Missense R131Q 16.05 0 1 (n= 1 hom)
rs141865425 0.003 Missense R238Q 22.2 2 3
N/A Novel Missense P307R 21.8 0 1
rs77401687 0.002 Missense K325T 18.18 0 1
rs758750492 0.000004 Missense Y350H 15.7 0 2
rs146505280 0.0008 Missense R359C 20.1 1 1
N/A Novel Missense R433Q 17.35 0 1
rs202162624 0.002 Missense R450H 18.23 0 2
BANK1
GWAS SNPs
rs10516487 0.26 Missense R61H 13.9 56 (n= 26 hom) 59 (n= 9 hom)
NRLF SNPs
rs35978636 0.01 Missense W40C 29.8 6 10
rs201960198 0.0001 Missense D400G 27.4 0 1
aMinor allelic frequency by gnomAD
GWAS genome wide association study, NRLF novel, rare and low-frequency, Hom homozygous, HC healthy control, SLE systemic lupus erythematosus
Table 2 Rare nonsynonymous BLK variants found in healthy
controls
MAFa Type AA change CADD
BLK
rs142352008 0.002 Missense P39L 22.7
rs202053568 0.00003 Missense H55R 5.8
rs778435147 0.00006 Missense K84N 26.7
rs371256341 0.00002 Missense V101I 5.2
rs367628135 0.00002 Missense R115Q 25
rs763307492 0.000004 Missense G248A 24.1
aMinor allelic frequency by gnomAD
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10242-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2201 | https://doi.org/10.1038/s41467-019-10242-9 | www.nature.com/naturecommunications 5
mice and to provide help for autoantibody production in
humans38. Together, these data suggest that human BLK
phosphorylates IRF5 and the hypomorphic BLK alleles have
impaired phosphorylation of IRF5 and diminished IRF5-
mediated T1 IFN repression. Furthermore, a BLK allele
orthologous to the one found in SLE was found to contribute to
disease in lupus-prone mice.
BANK1 SNV enhances TRAF6-mediated nuclear IRF5 locali-
zation. BANK1, initially identified as a substrate of LYN, is a
scaffold protein lacking intrinsic kinase activity39. Scaffold proteins
may positively and negatively regulate intracellular signalling
pathways in innate and adaptive responses by controlling avail-
ability and post-translational modification of signaling proteins40.
When expressed in HEK293T cells BANK1 formed cytoplasmic
inclusion bodies in a proportion of cells (Fig. 6a) reminiscent of
TRAF6-containing sequestosomes. Indeed, we confirmed wild type
BANK1 colocalized with TRAF6, the sequestosome protein p62
(Fig. 6b), as well as with the deubiquitinating enzyme CYLD, which
plays a critical role in regulating TLR signaling by deubiquitinating
TRAF641 (Supplementary Fig. 7A). BANK1 also localized in cyto-
plasmic aggregates when co-expressed with MYD88 (Supplemen-
tary Fig. 7B). We confirmed that BANK1 formed a complex with
TRAF6 by coimmunoprecipitation upon expression in
HEK293T cells (Fig. 6c).
TRAF6 is known to ubiquitylate IRF5 resulting in activation
and subsequent nuclear localization of IRF5 and T1 IFN
production42. We thus hypothesized that BANK1 promotes
sequestration of TRAF6 in typical p62+ and CYLD+ sequesto-
somes, reducing TRAF6 ubiquitination and thereby dampening
IRF5 activation and induction of TI IFN (Fig. 7a). Consistent with
this hypothesis, expression of BANK1W40C lead to significantly
reduced formation of BANK1+ sequestosomes (Fig. 7b, c).
Furthermore, when expressed with TRAF6 and IRF5, WT
BANK1 significantly repressed TRAF6-mediated IRF5 nuclear
localization. By contrast, BANK1W40C could not repress TRAF6-
mediated IRF5 nuclear localization to the extent of WT BANK1
(Fig. 7d). These findings demonstrate that the scaffold protein
BANK1 regulates TRAF6 activity and hence IRF5 signaling, and
establish that BANK1W40C is a loss-of-function variant that
promotes T1 IFN activity.
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Discussion
Although SLE is the result of a combination of environmental and
intrinsic predispositions, genetic risk remains one of the most
potent risk factors9. GWAS have provided substantial advances in
identifying possible disease pathways, yet they have been less
informative about disease mechanisms43. This is because variants
identified by GWAS, which are typically found at high fre-
quencies, only modestly increase risk and in the significant
majority of cases have modest or no effect on protein function43.
The prevalent hypothesis to explain substantial genetic risk for
SLE with common, weak variants is that risk arises from the
cumulative burden of dozens of these GWAS alleles. However,
the expanding, but still small, list of monogenic causes of SLE
supports the notion that novel or rare gene variants that sig-
nificantly cripple the function of crucial DNA-sensing or
degrading enzymes, or complement factors involved in the
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removal of apoptotic cells, can cause severe and often early onset
SLE-like disease20. We show here that SLE patients are likely to
harbour two or more rare variants in genes implicated in SLE by
GWAS or involved in the regulation of T1 IFN. The main focus of
the study was to determine whether the variants found in SLE
patients were damaging and could contribute to disease, and if so,
whether they were more damaging than those found in controls.
We tested the functional consequences of mutations in two
genes: BLK, which harboured novel or rare variants in 10.5% of
SLE probands, and BANK1, encoding a known BLK interacting
partner and shown to act in epistasis with BLK30. Significantly, we
demonstrate that these rare variants exert measurable damaging
effects on protein function, ultimately leading to a common
endpoint of increased T1 IFN activity in human B cells. Excessive
TI IFN activity is a unifying feature in the majority of SLE
patients44. Moreover, since BANK1 and BLK are also expressed in
plasmacytoid dendritic cells26,28,29, it is likely that a similar failure
to repress TI IFN occurs in these cells, which are major producers
of these cytokines45. Thus, these data indicate that rare SNVs in
the GWAS-implicated genes BANK1 and BLK are associated with
development of lupus and related autoimmune diseases.
We identify a novel role for BLK in regulating T1 IFN
downstream of TLR7/8 signalling, and demonstrate that the rare
variants found in SLE patients impair the ability of BLK to repress
T1 IFN production. The incomplete penetrance of autoimmunity
in BLK heterozygous individuals and the absence of overt auto-
immunity in BlkR125W/R125W mice may be due to the differences
in environmental exposure to stimulants of T1 IFN such as viral
infection. It is also likely that there is increased redundancy of Blk
in mice, in which other Src family-kinases have been shown to
compensate for Blk deficiency37. Moreover, the presence of
additional lupus-predisposing gene variants in SLE patients may
enhance the BLK defects. Strikingly, we observed a distinct dif-
ference in the deleteriousness of rare variants in BLK in HC and
SLE, suggesting that quality (degree of damage to protein func-
tion) rather than quantity (number of rare variants) may be a
more important determinant of contribution of rare variants to
disease.
BANK1, a scaffold protein, lacks intrinsic kinase activity and
may regulate signalling events by localization or sequestration of
significant intracellular signalling proteins. Here, we show that a
low-frequency (MAF < 2%) BANK1 variant diminishes localiza-
tion of BANK1 to sequestosomes, likely altering recruitment of
TRAF6 and CYLD to these regulatory structures. This is asso-
ciated with enhanced nuclear localization of IRF5, which is a
positive regulator of TI IFN transcription46. Since BANK1 is a
direct target of BLK phosphorylation, and BANK and BLK have
been previously shown to act in epistasis30, BLK’s capacity to
repress TI-IFN is probably related to its ability to regulate
BANK1 localization to sequestosomes and as a consequence,
regulate sequestosome homeostasis and TRAF6 activity.
Our demonstration that rare gene variants in GWAS-identified
SLE risk genes are damaging, and that these occur in a large
fraction of SLE patients supports the notion that rare variants, as
shown in other common and genetically complex conditions16,17,
contribute to SLE pathogenesis. Furthermore, the co-segregation
of variants in BANK1 and BLK in two families suggests that
sporadic lupus may occur upon inheritance or de novo occur-
rence of two or more rare variants with strong effects that act
together to cause disease.
Together, our findings demonstrate a role of rare BLK and
BANK1 variants in SLE and may offer an alternative explanation
for the association of some common variants in linkage dis-
equilibrium. Identification of rare variants as causes of lupus and
related systemic autoimmune disorders through whole exome
sequencing provides an approach intermediate between GWAS
and conventional mapping. An approach that demands func-
tional verification, but if provided, as we show here, can also yield
novel insights into disease mechanisms and novel targets for
treatment.
Methods
Human patients and DNA sequencing. Written informed consent was obtained
as part of the Australian Point Mutation in Systemic Lupus Erythematosus study
(APOSLE) and the Centre for Personalised Immunology program. The study was
approved by and complies with all relevant ethical regulations of the Australian
National University and ACT Health Human Ethics Committees. SLE cohort 1 and
2 were both recruited in Australia, processed and sequenced on similar platforms.
These two cohorts were recruited sequentially, with SLE cohort 1 recruited between
2008 and 2014 and SLE cohort 2 recruited between 2015 and 2017. Saliva was
collected in Oragene™ DNA self-collection kits and purified using PrepIT™ DNA
purification kits (Oragene) and treated with Ribonuclease A (Qiagen Cat# 19101).
DNA samples were enriched with Human SureSelect XT2 All Exon V4 Kit and
sequenced by Illumina HiSeq 2000 (Illumina, Inc.). WES had 21% low or uncov-
ered exon bases compared with 4% low or uncovered exon bases for WGS.
Bioinformatic analysis was performed at JCSMR, ANU. Raw sequence reads were
aligned to the reference genome (Hg19) and single-nucleotide variants and small
insertions and deletions called using GATK. Results were scored based on reported
minor allelic frequency (MAF), Polyphen2 score, expression in immune tissues and
reported mouse phenotypes. All SNVs of interest in BLK and BANK1 were con-
firmed by Sanger sequencing. Amplifluor to detect BANK1W40C and BLKR131W in
the APOSLE cohort was performed using the CHEMICON Amplifluor SNPs HT
Genotyping System Fam-Joe kit S7909 (Merck-Millipore). The 45 and Up47,48 and
ASPREE49 datasets were used as reference healthy controls, accessed through the
MGRB Collaborative (http://sgc.garvan.org.au/mgrb/initiatives).
WES/WGS data processing and batch correction. Probes were filtered out if the
detection p value was greater than 0.01 for at least 100% of the samples. All data
values <10 were set to 10 and then the data was log2 transformed. An additional
filter selecting the 75% most variable transcripts was performed, leaving a total
18,004 probes for analysis. Principal variance component analysis (PVCA) was
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conducted to identify undesirable sources of technical variability within the data
and batch correction was applied to correct for this technical variation. Both PVCA
and batch correction were conducted using JMP Genomics 7.0 (SAS Institute)
analysis software.
Determination of ethnicity by WES/WGS. We determined each individual’s
ethnicity utilizing GEMTools50–52 with genotypes across 23,556 sites53 extracted
from all 2504 Phase 3 samples of the 1000Genomes project54 to cluster our
230 samples individually into corresponding 1000Genomes superpopulations
which directly correspond to 6 populations within gnomAD (AFR, AMR, EAS,
FIN, NFE, and SAS). In all 230 GEMTools clustering runs (where the only non-
default parameter was setting maximum individual cluster size to 114 to match the
maximal sample size of 1000Genomes’ 26 populations), each of our samples fell
unambiguously within a population-homogenous cluster which was assigned as its
best-matching population. Admixture was determined in our sample cohorts using
rADMIXTURE, an implementation of the ADMIXTURE algorithm55 to correct for
population stratification, applied on the Dodecad K7b (http://dodecad.blogspot.
com/2012/01/k12b-and-k7b-calculators.html) global ancestry reference panel. This
method, though accurate for determining ancestral population components across
continents, was not suited for binning our samples into an admixed gnomAD
population like AMR, thus we used our GEMTools-derived best-matching popu-
lation to select each sample’s ethnically matched gnomAD population frequency.
RNA-expression analysis. Whole blood was collected in acid citrate dextrose
(ACD) tubes. RNA was extracted from whole blood (5′ Prime Perfect Pure kit) and
stored at −80 °C until use. Differential gene expression analysis was performed
using linear modeling with the Limma package56. Gene-set analysis was conducted
using the QuSAGE algorithm57, which tests whether the average log2-fold change
of a gene set is different from 0 and takes into account the correlations of the genes
by incorporating an estimate of the variance inflation factor of the gene set. Module
maps were generated as reported previously58.
Expression vectors and mutagenesis. The following expression vectors were
obtained: untagged BLK (OriGene Technologies), myc-LYN (GeneCopoeia, Inc.),
untagged IRF5 (OriGene Technologies). BANK1-V5 was a gift from C. Castillejo-
López (Uppsala University). Mutagenesis was performed using the Quikchange I
and II Site directed mutagenesis protocols (Agilent Technologies). IFNβ luciferase
(Addgene)59 pRL-CMV (Promega). pCMV-HA-MyD88 was a gift from Bruce
Beutler (Addgene plasmid # 12287), pX330-U6-Chimeric_BB-CBh-hSpCas9 was a
gift from Feng Zhang (Addgene plasmid # 42230).
Antibodies. Antibodies for western blotting, immunofluorescence imaging, and
coimmunoprecipitation studies were as follows: mouse anti-human BLK (SC-
65980; Santa Cruz), Mouse anti-V5 (clone SV5-Pk1, MCA1360, BioRad); mouse
anti-FLAG M2 (F1804; Sigma); Rabbit anti-LYN (06–207, EMD Millipore); mouse
anti phospho tyrosine-horseradish peroxidase (HRP) (R&D Systems); IRF5
(Abcam) and monoclonal mouse anti-CD71 (transferrin receptor) antibody
(C2063, Sigma). Secondary antibodies were conjugated to HRP (Jackson Immu-
noResearch), Alexa 568 or Alexa 488 (Molecular Probes, Invitrogen). Indo-1 AM
was from ThermoFisher and anti-IgM from Jackson Immunoresearch. All FACS
and microscopy work was carried out at the Microscopy and Cytometry Facility,
Australian National University.
Flow cytometry. The study was approved by and mouse handling complies with
all relevant ethical regulations of the Australian National University Ethics
Comittee. Spleens were isolated as single-cell suspensions after red blood cell lysis.
To stain for surface markers, we incubated cells in the antibody mixture diluted in
ice-cold staining buffer (2% fetal calf serum in phosphate-buffered saline). Ramos
cells were loaded with Indo-1 AM at 37 °C for 2 h before being stimulated at 37°
with anti-Fab(2) antibody. An LSRII or Fortessa Flow Cytometer with FACSDiva
software were used for flow cytometry acquisition, and FlowJo (Tree Star) was used
for analysis.
Transfection, immunoprecipitation, and western blotting. HEK 293T cells were
transfected (Lipofectamine 2000; Life Technologies) with the relevant plasmids as
per manufacturer’s recommendation. Cells were lyzed using NP-40 lysis buffer and
immunoprecipitated with the relevant antibody using Protein G Sepharose (GE
Healthcare) and the relevant antibody. For coimmunoprecipitation experiments
transferrin receptor was used as isotype control. Immunoprecipitants were resus-
pended in SDS (sodium dodecyl sulfate)-buffer and boiled prior to electrophoresis
on 8% SDS-polyacrylamide gel electrophoresis gels. Gels were transferred to
nitrocellulose membranes (BioRad Laboratories), blocked overnight (TBST+ skim
milk powder; or 5% bovine serum albumin for phosphotyrosine blots) and probed
with the relevant primary and secondary antibodies. Membranes were developed
with enhanced chemiluminescence developer (Western Lightning Plus ECL; Perkin
Elmer).
DLAs and electroporation. HEK293T cells were transfected with an IFN-β luci-
ferase reporter, pRL-CMV (10 ng; Promega) Renilla luciferase control reporter,
pcDNA 3.1 and indicated vectors and 24 h later dual luciferase assays (DLAs) were
performed as per published protocols60,61. For CpG response assays, TLR9-
HEK239s (Invivogen) were transfected using lipofectamine with indicated vectors,
IFNβ-luciferase and renilla reporters before being stimulated after 24 h with 5 µg/
ml CpG (ODN 2006, InvivoGen). The Burkitt’s lymphoma cell line Ramos was
nucleofected with the IFN-β luciferase reporter and pRL-CMV using the NEON
FLAG-TRAF6
FLAG-TRAF6
BANK1-V5
BANK1-V5
p62
p62DAPI
DAPI
DAPI MERGE
MERGE
MERGE
DAPI BANK1-V5 MERGE
IP
: F
LA
G
(T
RA
F6
)
W
CE
IP
: B
AN
K1
W
CE
IP
: T
FR
C 
IB: BANK1
IB: FLAG
(TRAF6)
BANK1
TRAF6
+ + + +
+++ –
–
+
a
b
c
Fig. 6 BANKW40C impairs TRAF6 localization to p62+ sequestosomes. a
Indirect immunofluorescence staining of HEK293T cells transfected
with wild type BANK1-V5 and stained with a BANK1 antibody. Scale bar is
50 μm. DNA was stained with DAPI (blue). b Indirect immunofluorescence
staining of HEK293T cells cotransfected with the cDNA constructs FLAG-
TRAF6 and BANK1-V5 (top and middle panels) or with BANK1-V5 alone
(bottom panel). Top panel: FLAG-TRAF6 was stained with a TRAF6
antibody (green) and BANK1-V5 was stained with a V5 antibody (red).
Middle panel: FLAG-TRAF6 was stained with a TRAF6 antibody (red) and
endogenous p62/SQSTM1 protein was labelled with a p62 antibody
(green). Bottom panel: BANK1-V5 was stained with a BANK1 antibody (red)
and endogenous p62/SQSTM1 protein was labelled with a p62 antibody
(green). DNA was stained with DAPI (blue). Scale bar 50 μm.
c Coimmunoprecipitation of BANK1-V5 and FLAG-TRAF6 from
HEK293T cells demonstrating a two-way interaction. BANK1-V5 was pulled
down using a BANK1 Ab and FLAG-TRAF6 with a FLAG antibody. TFRC
transferrin receptor, isotype control, WCE whole-cytoplasmic extract
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10242-9 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:2201 | https://doi.org/10.1038/s41467-019-10242-9 | www.nature.com/naturecommunications 9
transfection system (ThermoFisher Scientific) according to the manufacturer’s
instructions.
CRISPR-Cas9 genome editing of human B-cell lines. The vector px33062
(Addgene), which expresses Cas9 and the sgRNA, was linearized with BbsI and gel-
purified. A pair of complementary 18mer oligos targeting a single site within the
genome (primer sequences available upon request) were annealed and ligated to
the linearized vector. pX330 expressing the sgRNA of interest was transfected along
with an mcherry plasmid into the Burkitt’s lymphoma cell line Ramos using the
NEON transfection system (ThermoFisher Scientific) according to the manu-
facturers’ instructions. mcherry+ single cells were sorted 24–48 h later into 96-well
plates and individual clones expanded until confluent. gDNA was extracted by
digesting cells with proteinase K (0.1% Tween20, 100 μM EDTA, 500 μg/mL
Proteinase K, 1× high fidelity Phusion buffer) at 56 °C for 40 min, followed by
incubation at 95 °C for 8 min. A region of approximately 300 bp flanking the
variant was PCR amplified (primer sequences available on request) using Phusion
DNA Polymerase II (ThermoFisher Scientific) and presence of the mutation
confirmed by Sanger sequencing. All sequencing was carried out at the ACRF
Biomolecular Resource Facility and Genome Discovery Unit, Australian National
University.
CRISPR-Cas9-mediated genome-editing of mouse zygotes. C57BL/6 mice were
housed under specific pathogen-free conditions. All mouse procedures have been
approved by the Australian National University Animal Experimentation Ethics
Committee. (AEEC A2014/058 and A2014/016) under the NHMRC Australian
code of practice. Blk gRNA and Cas9 protein were obtained from PNABio. Oligo
and ssOligos were purchased from IDT (sequences available on request). C57BL/
6Ncrl female mice (4–5 weeks old) were superovulated with Pregnant Mare Serum
Gonadotrophin (PMSG) 5UI day 1 and Human Chorionic Gonadotrophin hor-
mone (HCG) 5UI day 3. After detection of a vaginal plug of the superovulated
females, mouse zygotes were harvested from the ampullae and were placed in
KSOM medium (Sigma). Cas9n protein (100 ng/µl) was co-injected with a mixture
of sgRNA (50 ng/µl each) and ssOligo (100 ng/µl) into the cytoplasm of the fer-
tilized eggs into M2 medium (Sigma). After micro-injection, the zygotes were
incubated overnight at 37 °C and 5% CO2 and two-cell stage embryos were sur-
gically transferred into the uterus of pseudopregnant CD1 recipient females at 2.5
dpc. Three weeks after birth mouse ears were punched. DNA was extracted and
Sanger sequencing performed to confirm the mutations. All the mouse zygote
preparation and micro-injection was carried out at the Australian Phenomics
Facility, Australian National University. The sequencing was carried out at the
ACRF Biomolecular Resource Facility and Genome Discovery Unit, Australian
National University.
qPCR. Total RNA was extracted from splenocytes stimulated in the presence of
R848 for 24 h using Trizol (Invitrogen). cDNA was synthesized using superscript
III (Thermo) or miscript (Qiagen) according to manufacturer’s instructions.
Quantitative PCR (qPCR) was carried out using the SYBR green method with the
following primer sequences; Eif2ak (forward, 5′-ATGCACGGAGTAGCCAT-
TACG-3′; reverse-GACAATCCACCTTGTTTTCGT-3′), If44 (forward, 5′-
AACTGACTGCTCGCAATAATG-3′; reverse- GTAACA-
CAGCAATGCCTCTTGT-3′), Ifih1 (forward, 5′-AGATCAACACCTGTGGTAA-
CACC-3′; reverse-CTCTAGGGCCTCCACGAACA-3′), Igs15 (forward, 5′-
GGTGTCCGTGACTAACTCCAT-3′; reverse-TGGAAAGGGTAAGACCGTCCT-
3′), Irf7 (forward, 5′-GAGACTGGCTATTGGGGGAG-3′; reverse-GACC-
GAAATGCTTCCAGGG-3′), Oas2 (forward, 5′-AGTTCCTACTGACCCA-
GATCC-3′; reverse- AGAGGGCTCTTACTGGCACTT-3′), Oas3 (forward, 5′-
TCTGGGGTCGCTAAACATCAC-3′; reverse- GATGACGAGTTCGA-
CATCGGT-3′). Ct values were normalized to Gapdh (forward, 5′-
AATGTGTCCGTCGTGGAT-3′; reverse-CTCAGATGCCTGCTTCAC-3′) and
relative expression was calculated using the 2−ΔΔCt method63.
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Fig. 7 Impaired sequestration of TRAF6 by BANK1 increases nuclear IRF5. a Schematic of the role of BANK1 and BLK on regulation of T1 IFN production. Red
lines indicate negative regulation. b Indirect immunofluorescence staining of HEK293T cells expressing either wild type (top panels) or W40C (bottom
panels) BANK1-V5 cDNA constructs. BANK1 protein was detected using an antibody specific for the V5 tag (red). DNA was stained with DAPI (blue).
Scale bar 20 μm. c Quantification of the percentage of HEK293T cells expressing WT or W40C BANK1-V5 with cytoplasmic inclusion bodies. Cells were
transfected with 3 μg of the BANK1-V5 cDNA constructs and stained 72 h post transfection. Greyscale inserts show enlargements of the indicated cell
sections. Double blind cell counting was carried out on at least 100 cells per experiment with three experimental replicates. d Representative images of
indirect immunofluorescence staining of HEK293T cells expressing IRF5, FLAG-TRAF6 and either WT BANK1-V5 (top panel) or W40C BANK1-V5 (bottom
panel). IRF5 protein was detected using an antibody specific for IRF5 (green) and BANK1 was detected using an antibody recognizing the V5 tag (red).
Greyscale inserts show enlargements of the indicated cell. Scale bar 50 μm. Double blind cell counting was carried out on at least 100 cells per experiment
with n= 3 experimental replicates. Bar graph represents quantification of the percentage of nuclear IRF5 as a proportion of the total IRF5 per cell based on
indirect immunofluorescence staining of HEK293T cells expressing IRF5, FLAG-TRAF6 and either WT BANK1-V5 or W40C BANK1-V5 (as in (d)).
Quantification was performed using the ImageJ software64. (Centre line=median, box= 25th to 75th percentile, whiskers= range; *p < 0.05, **p < 0.01,
Mann–Whitney U, representative of two experimental replicates)
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Data availability
WES and WGS sequencing data of the 76 genes described in this article have been
deposited to the EGA database under the accession number EGAD00001004859 and are
accessible to all qualified researchers meeting the data access policy (EGAP00001001134)
as determined by the Data Access Committee (EGAC00001001157). The 45 and Up47,48
and ASPREE49 datasets were used as reference healthy controls, accessed through the
MGRB Collaborative (http://sgc.garvan.org.au/mgrb/initiatives) and are accessible to all
qualified researches meeting the MGRB data access policy (https://sgc.garvan.org.au/
terms/mgrb). All variants have been submitted to ClinVar (SUB4880889 and
SUB5484273). The microarray data have been deposited to the GEO database under the
accession number GSE126307.
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